120 related articles for article (PubMed ID: 30132588)
21. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
Lucas T; Astorga R;
Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
[TBL] [Abstract][Full Text] [Related]
22. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
Bajetta E; Procopio G; Catena L; Martinetti A; De Dosso S; Ricci S; Lecchi AS; Boscani PF; Iacobelli S; Carteni G; De Braud F; Loli P; Tartaglia A; Bajetta R; Ferrari L
Cancer; 2006 Nov; 107(10):2474-81. PubMed ID: 17054107
[TBL] [Abstract][Full Text] [Related]
23. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Pokuri VK; Fong MK; Iyer R
Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
[TBL] [Abstract][Full Text] [Related]
24. Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly.
Witek P; Mucha S; Ruchała M
Endokrynol Pol; 2016; 67(6):572-579. PubMed ID: 28042650
[TBL] [Abstract][Full Text] [Related]
25. Colorectal neuroendocrine neoplasms - update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne jelita grubego - uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)].
Starzyńska T; Londzin-Olesik M; Bednarczuk T; Bolanowski M; Borowska M; Chmielik E; Ćwikła JB; Foltyn W; Gisterek I; Handkiewicz-Junak D; Hubalewska-Dydejczyk A; Jarząb M; Junik R; Kajdaniuk D; Kamiński G; Kolasińska-Ćwikła A; Kowalska A; Królicki L; Kunikowska J; Kuśnierz K; Lewiński A; Liszka Ł; Marek B; Malczewska A; Nasierowska-Guttmejer A; Nowakowska-Duława E; Pavel ME; Pilch-Kowalczyk J; Reguła J; Rosiek V; Ruchała M; Rydzewska G; Siemińska L; Sowa-Staszczak A; Stojčev Z; Strzelczyk J; Studniarek M; Syrenicz A; Szczepkowski M; Wachuła E; Zajęcki W; Zemczak A; Zgliczyński W; Zieniewicz K; Kos-Kudła B
Endokrynol Pol; 2022; 73(3):584-611. PubMed ID: 36059175
[TBL] [Abstract][Full Text] [Related]
26. The safety of lanreotide for neuroendocrine tumor.
Godara A; Siddiqui NS; Byrne MM; Saif MW
Expert Opin Drug Saf; 2019 Jan; 18(1):1-10. PubMed ID: 30582380
[TBL] [Abstract][Full Text] [Related]
27. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly.
Abrams P; Alexopoulou O; Abs R; Maiter D; Verhelst J
Eur J Endocrinol; 2007 Nov; 157(5):571-7. PubMed ID: 17984236
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
Biermasz NR; Roelfsema F; Pereira AM; Romijn JA
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):223-34. PubMed ID: 19527094
[TBL] [Abstract][Full Text] [Related]
29. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
Ducreux M; Ruszniewski P; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Hammel P; Rougier P
Am J Gastroenterol; 2000 Nov; 95(11):3276-81. PubMed ID: 11095353
[TBL] [Abstract][Full Text] [Related]
30. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
[TBL] [Abstract][Full Text] [Related]
31. High flow oxygen therapy in intensive care and anaesthesiology.
Maciejewski D
Anaesthesiol Intensive Ther; 2019; 51(1):41-50. PubMed ID: 31280551
[TBL] [Abstract][Full Text] [Related]
32. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
[TBL] [Abstract][Full Text] [Related]
33. Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity With Lanreotide Autogel/Depot (LAN) Versus Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):6-7. PubMed ID: 27168103
[No Abstract] [Full Text] [Related]
34. Commentary: Somatostatin analogs-How we choose, and why.
Reidy-Lagunes D; Raj N; Saltz L
Semin Oncol; 2017 Apr; 44(2):157-158. PubMed ID: 28923214
[No Abstract] [Full Text] [Related]
35. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
[TBL] [Abstract][Full Text] [Related]
36. [Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients].
Caron P
Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 3):2S19-24. PubMed ID: 12037499
[TBL] [Abstract][Full Text] [Related]
37. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).
Khan MS; El-Khouly F; Davies P; Toumpanakis C; Caplin ME
Aliment Pharmacol Ther; 2011 Jul; 34(2):235-42. PubMed ID: 21585408
[TBL] [Abstract][Full Text] [Related]
38. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
Ruszniewski P; Valle JW; Lombard-Bohas C; Cuthbertson DJ; Perros P; Holubec L; Delle Fave G; Smith D; Niccoli P; Maisonobe P; Atlan P; Caplin ME;
Dig Liver Dis; 2016 May; 48(5):552-558. PubMed ID: 26917486
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers.
Antonijoan RM; Barbanoj MJ; Cordero JA; Peraire C; Obach R; Vallès J; Chérif-Cheikh R; Torres ML; Bismuth F; Montes M
J Pharm Pharmacol; 2004 Apr; 56(4):471-6. PubMed ID: 15099442
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic neuroendocrine neoplasms - update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne trzustki - uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)].
Kos-Kudła B; Rosiek V; Borowska M; Bednarczuk T; Bolanowski M; Chmielik E; Ćwikła JB; Foltyn W; Gisterek I; Handkiewicz-Junak D; Hubalewska-Dydejczyk A; Jarząb M; Junik R; Kajdaniuk D; Kamiński G; Kolasińska-Ćwikła A; Kowalska A; Królicki L; Kunikowska J; Kuśnierz K; Lewiński A; Liszka Ł; Londzin-Olesik M; Marek B; Malczewska A; Nasierowska-Guttmejer A; Nowakowska-Duława E; Pavel ME; Pilch-Kowalczyk J; Reguła J; Ruchała M; Rydzewska G; Siemińska L; Sowa-Staszczak A; Starzyńska T; Stojčev Z; Strzelczyk J; Studniarek M; Syrenicz A; Szczepkowski M; Wachuła E; Zajęcki W; Zemczak A; Zgliczyński W; Zieniewicz K
Endokrynol Pol; 2022; 73(3):491-548. PubMed ID: 36059173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
